|Bid||43.500 x 0|
|Ask||43.550 x 0|
|Day's Range||42.500 - 43.700|
|52 Week Range||35.000 - 87.000|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||40.32|
|Earnings Date||Mar 22, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||90.84|
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
Q4 2022 Amicus Therapeutics Inc Earnings Call
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a license agreement with GSK plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.
The Biden administration on Thursday added Chinese memory chipmaker YMTC and 21 "major" Chinese players in the artificial intelligence chip industry to a trade blacklist, broadening its crackdown on China's chip industry. YMTC, long in the crosshairs of the U.S. government, was added to the list over fears it could divert U.S. technology to previously blacklisted Chinese tech giants Huawei and Hikvision. The move, laid out in the Federal Register, will bar YMTC's suppliers from shipping U.S. goods to it without a difficult-to-obtain license.
The Commerce Department also removed nine Russian entities from the unverified list and addded them to the entity list because the United States has been unable to conduct site visits. Companies are added to the unverified list if the United States cannot complete on-site visits to determine if they can be trusted to receive sensitive U.S. technology exports, inspections which in China require approval from the commerce ministry.
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company from Kyoto University, today announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal antibody targeting USAG-1 for the treatment of congenital adentia.
WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective October 7, 2022. In February 2022, two subsidiaries of WuXi Biologics, namely, WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd., were placed on the UVL due to delayed verifications required for
WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony, in partnership with the Worcester Business Development Corporation (WBDC), to mark the completion of the steel frame for WuXi Biologics' newest commercial biomanufacturing facility. Located in The Reactory, Worcester's biomanufacturing park developed by WBDC, the 189,500 sq. ft. state-of-the-art facility is set for completion in 2024 and is expected
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
(Bloomberg) -- China’s heated rivalry with the US over tech supremacy is adding fresh pain points to the world’s second-largest stock market, as the Biden administration steps up efforts to reduce economic reliance on the Asian nation. Most Read from BloombergJapan to Restore Visa-Free Travel From Oct. 11 as Covid Pandemic Recedes South Korea President Caught on Hot Mic Insulting US CongressA Great Copper Squeeze Is Coming for the Global EconomyPutin's Order for 300,000 Fighters Drives Russians
WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced a 10-year USD$1.4 billion (S$2 billion) investment plan to expand the company's research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. This new site will add 120,000L biomanufacturing capacity to WuXi Biologics' global network by 2026 and is anticipated to employ 1,500 research,